Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)

Authors :: Blauvelt, A.
Guttman-Yassky, E.
Paller, A.S.
Simpson, E.L.
Cork, M.J.
Weisman, J.
Browning, J.
Soong, W.
Sun, X.
Chen, Z.
Kosloski, M.P.
Kamal, M.A.
Delevry, D.
Chuang, C.-C.
O’Malley, J.T.
Bansal, A.
Publication Year :: 2022
Publisher :: Springer Nature, 2022.
Abstract: Background\ud \ud For adolescent patients (aged ≥ 12 to

Tools